Cite
HARVARD Citation
Langley, R. et al. (2018). Efficacy and safety of continuous every‐2‐week dosing of ixekizumab over 52 weeks in patients with moderate‐to‐severe plaque psoriasis in a randomized phase III trial (IXORA‐P). British journal of dermatology. pp. 1315-1323. [Online].